Skip to main content
FERMENTA BIOTECH LIMITED logo

FERMENTA BIOTECH LIMITED — Investor Relations & Filings

Ticker · FERMENTA ISIN · INE225B01021 LEI · 335800VNTNWW8G1U9314 BSE.NS Manufacturing
Open in API
Filings indexed 671 across all filing types
Latest filing 2023-02-10 Regulatory Filings
Country IN India
Listing BSE.NS FERMENTA

About FERMENTA BIOTECH LIMITED

https://fermentabiotech.com

Fermenta Biotech Limited is a specialized biotechnology company primarily focused on the development and manufacture of Vitamin D3 (Cholecalciferol). As one of the few vertically integrated manufacturers globally, the company produces Vitamin D3 for diverse applications, including pharmaceuticals, dietary supplements, human nutrition, and animal feed. Beyond its core Vitamin D3 portfolio, the company offers a range of specialty enzymes, particularly for the synthesis of beta-lactam antibiotics, and provides environmental solutions through its biotechnology expertise. Fermenta Biotech emphasizes high-quality standards, maintaining various international certifications for its manufacturing facilities. Its product offerings extend to premixes and value-added formats designed to meet specific formulation requirements. The company serves a global clientele, leveraging its research and development capabilities to innovate in the fields of nutrition and biotechnology.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we inform you that the Company has received an intimation from its Registrar and ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to the stock exchange (BSE Limited) under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about the issue of a duplicate share certificate to a shareholder. The content is an official notification regarding share certificate issuance, not a financial report, earnings release, or management discussion. It does not contain financial data or analysis, nor does it announce voting results or capital changes. The document is a regulatory compliance announcement related to share certificates, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2023-02-10 English
We write to inform you that the Board of Directors of the Company at its meeting held on February 10, 2023 has, inter alia, approved the unaudited financial results for the quarter and ....
Regulatory Filings
2023-02-10 English
We write to inform you that the Board of Directors of the Company at its meeting held on February 10, 2023 has, inter alia, approved the unaudited financial results for the quarter and ....
Regulatory Filings
2023-02-10 English
Fermenta Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2023 ,inter alia, to consider and approve Meeting of the Board of Directors ....
Regulatory Filings Classification · 95% confidence The document is a notice from the company to the stock exchange about an upcoming Board Meeting scheduled to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2022. It also informs about the closure of the trading window in compliance with SEBI regulations. The document does not contain any financial data or results itself, nor does it include detailed financial analysis or reports. It is a regulatory announcement informing about the meeting and trading restrictions ahead of the financial results announcement. The document length is short (2552 characters), and it serves as a notification rather than a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such regulatory announcements that do not fit other specific categories.
2023-02-02 English
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we inform you that the Company has received an intimation from its Registrar and ....
Regulatory Filings Classification · 95% confidence The document is a short notice (1787 characters) informing the stock exchange (BSE Limited) about the issuance of a duplicate share certificate to a shareholder, pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It contains no financial statements, no management discussion, no earnings data, and no detailed report. It is an official regulatory communication about share certificate issuance, which fits the category of Regulatory Filings (RNS) as it does not fit into more specific categories like Share Issue/Capital Change (SHA) or Director's Dealing (DIRS). The document is not a report or announcement of a report, nor is it a certification or legal proceeding. Therefore, the best classification is Regulatory Filings (RNS).
2023-01-31 English
Pursuant to the provisions of Regulation 74(5) of SEBI (Depositories and Participants), Regulations 2018, for the quarter ended December 31, 2022, we hereby certify that on receipt of securities ....
Regulatory Filings
2023-01-30 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.